Research summaries for everyoneNot medical advice
MOTS-c research reference vial, Elevated Pharma

Research reference · Cellular Energy

MOTS-c

MOTS-c is a 16-residue peptide encoded in mitochondrial DNA. It was first described in 2015 and is studied in cell and animal models of metabolism and exercise.

Published by Elevated Pharma ·

Cellular EnergyPreclinical literature

Identity

What is MOTS-c?

A mitochondrial-derived peptide encoded within the 12S rRNA gene (sequence MRWQEMGYIFYPRKLR).

Research context

What has MOTS-c been studied for?

Most work is in cells and mice. Human studies so far measure natural MOTS-c levels in blood, for example after exercise; they do not test MOTS-c given as a drug.

Evidence boundary

What does the research not show?

Preclinical findings do not establish human safety, clinical effectiveness or a material specification.

U.S. status · November 7, 2026

Is MOTS-c FDA-approved?

FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 7–5, two abstentions). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.

Research updates

What’s new

Dated developments for MOTS-c, newest first. See all research updates.

  1. HHS interim compounding policy

    HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.

    Read the source
  2. FDA advisory committee votes

    FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).

    Read the source

Key studies

The main MOTS-c research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 264 PubMed records for MOTS-c · Counts and selections checked November 7, 2026.

Reference identifiers

MOTS-c identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
MOTS-c
Also indexed as
Mitochondrial open reading frame of the 12S rRNA-c
Sequence
MRWQEMGYIFYPRKLR
Molecular formula
C101H152N28O22S2
Molecular mass
2174.6 g/mol
PubChem CID
146675088

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.